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INTRODUCTION
The aromatase inhibitors (AIs) are well known anti-hor-
monal therapy in endocrine-responsive breast cancer 
patients as it inhibits the synthesis of estrogen. Post-
menopausal women with endocrine-responsive breast 
cancer in the adjuvant or metastatic settings are usually 
treated with AIs according to recent guidelines [1]. The 
AIs are used for at least 5 years in adjuvant treatment, 
so the long-term safety of AIs is important concern to 
patients who are taking AIs. 
Estrogen has atheroprotective effects by maintaining 
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Background/Aims: The aromatase inhibitors (AIs) are well known anti-hormonal 
therapy in endocrine-responsive breast cancer patients. It can lead to dyslipid-
emia and be the risk factor of cardiovascular disease due to low estrogen level. 
However, some recent studies comparing AIs with placebo have shown contro-
versial results. The aim of this study was to investigate lipid profiles, measure-
ment of carotid intima-media thickness (IMT) and the presence of plaque among 
endocrine-responsive breast cancer treated with AIs compared to ones that were 
not treated with AIs. 
Methods: A total of 85 postmenopausal women, who underwent breast cancer sur-
gery during the age of 50 to 64 without history of statin use were included. There 
were 42 patients who were treated with AIs over 1 year (group 1) and 43 patients 
without AIs use (group 2). Serum total cholesterol, high density lipoprotein cho-
lesterol, triglycerides, fasting blood glucose, carotid IMT, and presence of plaque 
were assessed. 
Results: The baseline characteristics were similar between two groups and there 
was no significant difference in carotid IMT irrespective of AIs administration. 
However, ultrasonographic evaluation of carotid artery revealed that the pres-
ence of plaque in AI users was significantly higher than in non-AI users (66.7% 
vs. 41.9%, p = 0.02; odds ratio, 4.21 in adjusted model; p = 0.01). History of diabetes 
was also the significant risk factor for the plaque formation. 
Conclusions: There was no significant difference in lipid profile itself between 
two groups, but more importantly the presence of the plaque was much higher 
indicating possible detrimental effect of AI on cardiovascular system. 
Keywords: Breast neoplasms; Aromatase inhibitors; Dyslipidemias; Cardiovascu-
lar diseases; Carotid plaque
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normal serum lipid profiles. Estrogen also alters the co-
agulation and fibrinolytic system, antioxidant system, 
and the production of vasoactive molecules [2]. And es-
trogen decline occurring after the menopause can influ-
ence the development of cardiovascular disease (CVD). 
Thus, the incidence of atherosclerotic disease increases 
in postmenopausal women [3]. 
As a result of AIs use, serum estrogen (including es-
trone, estradiol, and estrone sulfate) level was decreased 
over 90% in postmenopausal women with advanced 
breast cancer [4]. Due to absolute deficiency in estro-
gen level, it can also lead to dyslipidemia [5]. And drugs 
which alter lipid profiles could increase the risk of CVD 
by vascular atherosclerosis [6]. In addition, atheroscle-
rosis is one of the most important cause of morbidity 
and mortality even in patients with cancer [7]. For these 
reasons, the evaluation of the risk of CVD is important 
for breast cancer patients even more with the ones who 
are taking AIs. 
There have been lots of controversies on the effect of 
AIs to lipid profile or CVD risk. In the previous study 
with postmenopausal women aged 46 to 68 years, com-
paring the level of lipid profile before and after the treat-
ment of AIs (n = 20), a significant increase in total cho-
lesterol (p = 0.05) and low density lipoprotein cholesterol 
(LDL-C; p < 0.01) was noticed [8]. In a BIG (Breast Interna-
tional Group) 1-98 trial (n = 4,922) with postmenopausal 
women with the median age of 61 years, comparing to 
tamoxifen treatment group, patients on AIs experienced 
more frequent low-grade hypercholesterolemia (50.6% 
vs. 24.6%, p < 0.001) [9]. Meanwhile, in the MA.17 trial 
with postmenopausal women with the median age of 63 
years, Wasan et al. [10] reported that there was no signifi-
cant differences in lipid profile between the treatment 
group (AIs [n = 181] vs. placebo [n = 161]) in a random-
ized placebo-controlled trial with letrozole for 5 years in 
postmenopausal women with breast cancer. However, 
all these patients already received 5 years treatment with 
tamoxifen prior to enrollment. 
Several clinical data including MA.17 trial and ATAC 
(Arimidex, Tamoxifen, Alone or in Combination) trial, 
use of AIs showed no difference in risk of cardiovascu-
lar morbidity or mortality between AIs and tamoxifen 
treatment groups [11,12]. Meanwhile, in recent large-
scale studies from adjuvant trials have raised concerns 
that long-term use of AIs do increase the risk of cardio-
vascular events although odds ratio (OR) were different 
among subgroup of AIs [13,14]. In a meta-analysis of 
several randomized trials, the incidence of high grade 
cardiovascular events were increased in AIs users com-
paring with the patients who were receiving tamoxifen 
(relative risk, 1.31; 95% confidence interval [CI], 1.07 to 
1.60; p = 0.007; total n = 19,818) [13]. In a systematic review 
of 30,023 patients, longer duration of AIs use was asso-
ciated with increased CVD development (OR, 1.26; 95% 
CI, 1.10 to 1.43; p < 0.001) [14]. This potential AIs toxicity 
on CVD risk might be one of the reasons of lack of over-
all survival benefit despite improvements in disease free 
survival in AIs treatment group [14]. 
Long-term risk of atherosclerosis and CVD due to 
cancer treatment may become an important consider-
ation in the era of improved survival of breast cancer pa-
tients. It remains uncertain whether AI use may account 
for potential detrimental effects on the process of ath-
erosclerosis when used for longer duration [15]. Carotid 
ultrasonography, including the measurement of carotid 
intima-media thickness (IMT) and carotid plaque, has 
been known to be a reliable marker of early atheroscle-
rosis and cardiovascular risk. Thus, in this study, we in-
vestigated lipid profiles, actual measurement of carotid 
IMT and presence of plaque among endocrine-respon-
sive breast cancer treated with AIs compared with non-
AI treated women. 
METHODS
Subjects
We conducted a retrospective, cross-sectional study by 
using data retrieved from the electronic registry of a ter-
tiary-level, university-affiliated single institution (Sever-
ance Hospital, Yonsei University College of Medicine, 
Seoul, Korea). Eighty-five postmenopausal breast cancer 
subjects (age 50 to 64) who underwent surgery from Jan-
uary 2002 to October 2012 were included in this study. 
There were 42 patients who were treated with AIs. And 
there were 43 patients without any endocrine therapy. 
Considering anti-atherosclerotic effect of tamoxifen 
[16], patients who were treated with tamoxifen as the 
first line therapy was excluded. Also, we excluded pa-
tients who had history of statin therapy over 3 months 
prior to enrollment, since medications like statins may 
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alter lipid profile and IMT. 
This study was approved by the Institutional Review 
Board (IRB) of Severance Hospital, Yonsei University 
(No. 4-2018-1049) and obtaining informed consent form 
has been waivered by IRB.
Methods
Height, weight, and body mass index (BMI) were mea-
sured and the medical history of patients was taken. 
Serum total cholesterol, high density lipoprotein cho-
lesterol (HDL-C), triglycerides, fasting insulin, and fast-
ing blood glucose were assessed before the ultrasound 
evaluation. 
To evaluate insulin sensitivity or resistance, the quan-
titative insulin-sensitivity check index (QUICKI) [17] 
and the homeostasis model assessment of insulin re-
sistance (HOMA-IR) were calculated [18]. In calculation 
of QUICKI and HOMA-IR, patients who were receiving 
insulin treatment or have history of diabetes before the 
operation were excluded. 
B-mode ultrasonography of the carotid artery was 
performed using an ultrasound machine (LOGIQ9, GE 
Medical Systems, Milwaukee, WI, USA) with a 10-MHz 
linear transducer. The internal carotid artery, the ca-
rotid bulb, and the extracranial common carotid artery 
(CCA) in the neck were examined bilaterally. The IMT 
was measured as the distance between the blood-intima 
and media-adventitia interface. The mean IMT of the 
CCA was measured over a segment of the CCA that was 
1cm long, located approximately 2 cm below the carotid-
artery bulb [19]. 
The greatest thickness of IMT in the CCA was mea-
sured and defined as maximum IMT. The carotid 
plaque was defined as a focal structure encroaching into 
the arterial lumen or a focal thickening > 50% of the sur-
rounding wall [20]. All measurements were performed 
by the same qualified observer who was blinded the ac-
tual status of the patient. 
Statistics
All statistical analyses were performed with SPSS version 
20.0 (IBM Co., Armonk, NY, USA). All values are report-
ed as mean ± SD with parametric data, median (inter-
quartile range) with non-parametric data, and real num-
bers of subjects with the percentage in parentheses. The 
normality of the distribution of continuous variables 
was examined using Shapiro-Wilk test. Between-group 
differences of the average were compared using the un-
paired t test for parametric data, and the Mann-Whitney 
U test was used for non-parametric data. Between-group 
differences of numbers and percentages were compared 
using a chi-square test. Multivariate logistic regression 
analysis was used with adjustment for variables with 
significant associations at the level of p < 0.05 in uni-
variate models and variables which were known as risk 
factors of carotid plaque formation including dyslipid-
emia, concurrent chemotherapy, and radiotherapy. For 
all tests, p < 0.05 was considered statistically significant.
RESULTS
Clinical characteristics of study population
The clinical characteristics of patients are given in Ta-
ble 1. There were no significant differences in the age at 
the time of surgery and ultrasonography, BMI, fasting 
blood glucose, QUICKI, HOMA-IR, and lipid profile 
between two groups. History of diabetes, TNM (tumor, 
nodes and metastasis) stage and elapsed time to IMT 
after surgery were also similar in each group. More pa-
tients conducted either neoadjuvant or adjuvant chemo-
therapy in non-AI group (33/43, 76.7%) than in AI group 
(21/42, 50.0%; p = 0.010) (Table 1). Patients who received 
radiotherapy after the surgery showed no significant 
differences between two groups. 
Measurement of IMT and carotid plaque 
Even though there was increased tendency (median value 
of mean IMT 0.65 mm in AIs use group vs. 0.63 mm in 
non-AI use group, maximum IMT 0.74 mm in AIs vs. 0.72 
mm in non-AIs), there was no significant difference in ca-
rotid IMT irrespective of AIs use (Fig. 1). However, ultra-
sonographic evaluation of carotid artery revealed that the 
presence of plaque in AI group was significantly higher 
than in non-AI group (66.7 % vs. 41.9 %, p = 0.022) (Fig. 2).
Independent risk factors of plaque presence 
Univariate and multivariate logistic regression was per-
formed for all 85 patients. In univariate analysis, age at 
the time of ultrasonography (OR, 1.15; p = 0.012), the use 
of AIs (OR, 2.78; p = 0.023), and the history of diabetes 
(OR, 4.23; p = 0.019) increased the risk of carotid plaque 
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presence significantly. In multivariate analysis, the use 
of AIs was an independent predictor of the presence of 
plaque in carotid ultrasonography (OR, 4.21; p = 0.010). 
History of diabetes was also a strong risk factor for the 
plaque (OR, 6.69; p = 0.011). The age at the time of ultra-
sonography was also related to the plaque presence (OR, 
1.12; p = 0.048). However, BMI, lipid profile, stage at the 
time of primary breast cancer, history of chemotherapy, 
and radiotherapy did not increase the risk of plaque for-
mation (Table 2). 
The history of diabetes was the strongest risk factor for 
plaque formation, and this factor can mimic the effect of 
AIs use. So, we also conducted multivariate analysis after 
excluding the patients with diabetes. And still, AIs was 
one of the strong risk factors for carotid plaque presence 
(n = 66; OR, 3.55; p = 0.031) (Supplementary Table 1).
DISCUSSION
AIs are widely used in patients with endocrine-respon-
sive breast cancer to reduce the risk of recurrence [21]. 
AIs inhibit the synthesis of estrogen and are recom-
mended over 5 years [21]. It causes several side effects in-
cluding hot flushes, musculoskeletal disorder, low bone 
mass, and dyslipidemia [22]. 
Table 1. Baseline characteristics of the study population 
Characteristic AI user  (n = 42) Non-AI user (n = 43) p value
Duration of AIs use, mon 34.3 ± 16.9 - -
Age at the time of operation, yra 56.5 (8) 54.0 (7) 0.143
Age at the time of ultrasonography, yra 60.0 (8) 57.0 (7) 0.066
Elapsed time to IMT after operation, mona 33.0 (20) 30.0 (40) 0.187
History of DM 8 (19.0) 11 (25.6) 0.470
Duration of DM, yra 9.8 (11.0) 6.6 (2.0) 0.477
History of HTN 13 (31.0) 9 (21.4) 0.457
Use of antiplateletes 6 (14.3) 4 (9.5) 0.736
Use of statin 20 (60.6) 24 (70.6) 0.547
Smoking 0 1 (2.4) 0.991
TNM stage (≥ 2a) 22 (52.4) 18 (41.9) 0.331
BMI, kg/m2 24.1 ± 2.4 24.1 ± 2.6 0.999
FBS, mg/dLa  97.5 (16) 99.0 (15) 0.812
Total cholesterol, mg/dL 206.1 ± 42.1 216.7 ± 39.5 0.233
HDL-C, mg/dL 53.7 ± 13.4 53.4 ± 10.3 0.902
Triglycerides, mg/dLa 123.0 (77) 129.0 (74) 0.916
LDL-C, mg/dL 122.5 ± 37.6 129.5 ± 41.0 0.415
QUICKIa 0.35 ± 0.01 0.35 ± 0.01 0.735
HOMA-IRa 1.89 (2.12) 1.75 (1.67) 0.872
Chemotherapy 21 (50.0) 33 (76.7) 0.010
Radiotherapy 24 (57.1) 22 (51.2) 0.580
Chemotherapy plus radiotherapy 12 (28.6) 18 (41.9) 0.200
Values are presented as mean ± SD or number (%).
AI, aromatase inhibitor; IMT, intima-media thickness; DM, diabetes mellitus, HTN, hypertension; TMN, tumor, nodes and 
metastasis; BMI, body mass index; FBS, fasting blood sugar; HDL-C, high density lipoprotein cholesterol; LDL-C, low density 
lipoprotein cholesterol; QUICKI, quantitative insulin-sensitivity check index; HOMA-IR, homeostasis model assessment of 
insulin resistance.
aMedian (interquartile range) with non-parametric data. Differences between groups of patients were analyzed by the chi-
square test, independent t test, and Mann-Whitney U test.
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In our study, there was no significant difference be-
tween two groups regarding lipid profile (total cho-
lesterol, HDL-C, LDL-C, and triglycerides). And there 
was no significant difference in median and maximum 
IMT between two groups. Surprisingly, the use of AIs 
was associated with an increased risk of carotid plaque 
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Figure 1. Intima-media thickness (IMT) difference between 
two groups was compared by Mann-Whitney U test. Data are 
the median (interquartile range) of the non-parametric data 
and real numbers of subjects with the percentage in paren-
theses. AI, aromatase inhibitor.
Figure 2. Differences in presence of carotid plaque between 
two groups were compared by chi-square test. AI, aromatase 
inhibitor.
Table 2. Risk factors of plaque formation 
Variable
Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Age at the time of ultrasonography, yr 1.15 (1.03–1.29) 0.012a 1.12 (1.00–1.26) 0.048a
BMI 1.13 (0.94–1.35) 0.191
FBS 1.03 (0.99–1.06) 0.114
Total cholesterol 1.00 (0.99–1.01) 0.570 1.01 (1.00–1.03) 0.056
HDL-C 1.00 (0.97–1.04) 0.816
Triglyceride 1.00 (0.99–1.01) 0.955
LDL-C 1.00 (0.99–1.01) 0.724
TNM stage (≥ 2a) 1.07 (0.46–2.52) 0.878
Chemotherapy 1.17 (0.48–2.84) 0.726
Radiotherapy 1.02 (0.43–2.40) 0.963
CTx plus RTx 1.17 (0.48–2.87) 0.728 1.78 (0.60–5.24) 0.297
AIs use 2.78 (1.15–6.17) 0.023a 4.21 (1.42–12.5) 0.010a
History of DM 4.23 (1.27–14.1) 0.019a 6.69 (1.54–29.0) 0.011a
Multivariate analysis was performed using multiple logistic regression. Variables with significant associations at the level of 
p < 0.05 in univariate models and variables which were known as risk factors of carotid plaque formation including dyslipid-
emia, concurrent chemotherapy, and radiotherapy were included in adjustment. 
OR, odds ratio; CI, confidence interval; BMI, body mass index; FBS, fasting blood sugar; HDL-C, high density lipoprotein 
cholesterol; LDL-C, low density lipoprotein cholesterol, TNM, tumor, nodes and metastasis; CTx, chemotherapy; RTx, radio-
therapy; AI, aromatase inhibitor; DM, diabetes mellitus. 
ap values less than 0.05.
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and this association was independent of age, cholester-
ol, history of chemotherapy, radiotherapy, or diabetes 
(adjusted OR, 4.21; 95% CI, 1.42 to 12.5). In a national co-
hort study of 375 women, age-adjusted OR of smoking in 
presence of carotid plaque was 3.7 (95% CI, 1.9 to 7.2) [23]. 
This shows that the use of AIs has similar strong associ-
ations as smoking with the presence of carotid plaque. 
Several studies have raised concerns that long-term 
use of AIs may increase the risk of cardiovascular events 
[14,24]. In a recent meta-analysis with eight eligible 
RTCs (34,070 patients), both monotherapy with AI and 
sequenced therapy (tamoxifen switched to an AI) were 
associated with significantly higher risk of cardiovas-
cular events (OR, 1.20 and 1.15; p = 0.030, p = 0.003, re-
spectively), furthermore, sequenced therapy was found 
to have surprisingly increased risk of thromboembolic 
events (OR, 1.89; p = 0.005) [24]. There also was a recent 
population-based observational study with 74 women 
from heterogeneous population who received either AIs 
or tamoxifen and subsequently underwent cardiac angi-
ography and the use of AIs was associated with a signifi-
cant hazard for cardiovascular event (hazard ratio, 3.23; 
95% CI, 1.26 to 8.25; p = 0.01) [25].
Thus, risk identification and early diagnosis of asymp-
tomatic CVD is important for patients in endocrine-
responsive breast cancer. For this reason, the measure-
ment of carotid IMT has been widely recommended 
for the assessment of subclinical atherosclerosis in the 
asymptomatic individuals with an intermediate risk of 
CVD and the CCA is known to be the most reproducible 
segment for the measurement [26,27]. In previous stud-
ies, carotid maximum IMT has been used in the screen-
ing asymptomatic type 2 diabetic patients with severe 
CVD [20]. Recently, ultrasonic tissue characterization of 
carotid plaque has been also used in improving the pre-
diction of coronary artery disease (CAD) events [28]. Fur-
thermore several studies have shown that the presence 
of carotid plaque is better than that of carotid IMT for 
predicting future cardiovascular events [20,29,30]. 
Carotid artery IMT and plaque are both the mark-
ers of systemic atherosclerosis and predictors of CVD 
development [31]. However, IMT and carotid plaque 
showed different patterns of cardiovascular complica-
tion reflecting different biological aspects of atherogen-
esis. IMT on CCA was strongly related to increased risk 
for stroke, whereas carotid plaque was more directly re-
lated to ischemic heart disease [23], On the other words, 
the presence of carotid plaque, rather than the thickness 
of IMT, was shown to be a more powerful predictor of 
CVD development [23,32]. And the presence of carotid 
plaques was confirmed as a reliable positive predictive 
factor for CAD, although a statistically significant but 
weak correlation between IMT of the CCA and severity 
of CAD was found [33]. 
Choi et al. [34] reported that selective estrogen recep-
tor modulation (raloxifene treatment in this study) re-
duced arterial plaque volume and enhanced mechanical 
stability of vascular calcification. In this study, analysis 
for plaque revealed reductions in inflammatory mate-
rials like cyclooxygenase-2 (COX-2), matrix metallo-
proteinase-1 (MMP-1), monocyte chemoattractant pro-
tein-1 (MCP-1), and less macrophage infiltration with 
upregulation of estrogen receptor α (ERα). In other 
animal studies raloxifene not only improved endothe-
lial dysfunction by normalizing endothelial nitric oxide 
synthase 3 (eNOS) expression but also reduced the size 
of artherosclerotic lesion [35]. And endothelial ERα is 
known to be a major mediator in atheroprotection [36]. 
Base on above findings, we can speculate that the use 
of AIs, which induce extreme estrogen deprivation, can 
increase plaque formation by the inflammatory effects 
in vascular wall without altering serum cholesterol level 
by absolute deficient estrogen. 
In this study, age and history of diabetes were also re-
lated to formation of carotid plaque. Rundek et al. [37] 
reported that number of carotid plaques was increased 
with age and history of diabetes. Cardiovascular effects 
of adjuvant systemic chemotherapy and radiotherapy 
are still controversial. Zambetti et al. [38] reported that 
adjuvant chemotherapy did not lead to cardiac sequelae. 
Indeed, there are several reports that radiotherapy with 
or without adjuvant chemotherapy are associated with 
an increased risk of CVD [39]. In this study, both sys-
temic chemotherapy and radiotherapy did not increase 
the risk of carotid plaque formation statistically. 
There are some limitations in our study, first, it was a 
retrospective study and the number of subjects in each 
group was relatively small. Second, IMT was assessed 
only once after treatment with AI. Thus, we conducted 
multivariate analysis with well-known risk factors for 
carotid plaque formation. Although smoking is one the 
strongest risk factors, it was not included in our assess-
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ment as there was only one participant in our study, 
who had history of smoking or currently smoked. Third, 
the elapsed time to carotid ultrasonography after sur-
gery was relatively short in this population (mean 35.4 
months) to confirm any detrimental effects of AIs to 
IMT. Increased IMT means the deposition of extracel-
lular matrix material and the smooth muscle cell pro-
liferation resulted from a chronic adaptive process [37]. 
Ando et al. [40] reported that the IMT on CCA increased 
only 0.06 mm/10 years with presence of plaque in the 
bulbs (PLQ-BLB) and 0.04 mm/10 years without PLQ-
BLB. And in the healthy, and normolipidemic subjects, 
the estimated yearly increase in IMT was only 0.007 mm 
in women [41]. Based on above evidence, it would have 
been impossible to note the difference in IMT after such 
a short elapsed time unless the participants already had 
IMT at baseline. Also, carotid IMT, compared to carotid 
plaque, is less influenced by environmental factors [42]. 
Forth, in our study, only the presence of plaque was 
measured. For further evaluation and exact prediction 
of CAD, plaque area [32], and volume [43] can be used, al-
though these methods can be more expensive, complex, 
and time-consuming. However, they were not available 
in our study because they were not part of our standard 
carotid ultrasonography. Lastly, there could be a selec-
tion bias. Again, we conducted multivariate analysis in 
which still led AI use as one of the strongest risk factors 
of carotid plaque formation. 
We conclude that AIs use indeed affected endo-
crine-responsive breast cancer patients by forming more 
carotid plaque regardless of lipid profiles itself. Close 
monitoring of these patients on cardiovascular events 
would be important. And further prospective, long term 
studies comparing AIs with placebo will be needed to 
understand the long-term safety of AIs treatment.
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Supplementary Table 1. For patients without diabetes mellitus history (n = 66) 
Variable
Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Age at the time of ultrasonography, yr 1.10 (0.98–1.23) 0.115 1.10 (0.97–1.25) 0.144
BMI 1.12 (0.92–1.37) 0.256
FBS 1.01 (0.95–1.08) 0.678
Total cholesterol 1.01 (1.00–1.02) 0.206 1.01 (1.00–1.03) 0.091
HDL-C 1.03 (0.98–1.07) 0.222
Triglyceride 1.00 (0.99–1.01) 0.913
LDL-C 1.00 (0.99–1.01) 0.873
TNM stage (≥ 2a) 1.44 (0.55–3.81) 0.460
Chemotherapy 1.06 (0.39–2.84) 0.915
Radiotherapy 1.50 (0.56–3.99) 0.421
CTx plus RTx 1.38 (0.50–3.81) 0.536 1.98 (0.60–6.51) 0.262
AIs use 2.50 (0.93–6.69) 0.068a 3.55 (1.13–11.2) 0.031a
Multivariate analysis was performed using multiple logistic regression. Variables with significant associations at the level of 
p < 0.05 in univariate models and variables which were known as risk factors of carotid plaque formation including dyslipid-
emia, concurrent chemotherapy, and radiotherapy were included in adjustment.
OR, odds ratio; CI, confidence interval; BMI, body mass index; FBS, fasting blood sugar; HDL-C, high density lipoprotein 
cholesterol; LDL-C, low density lipoprotein cholesterol, TNM, tumor, nodes and metastasis; CTx, chemotherapy; RTx, radio-
therapy; AI, aromatase inhibitor. 
ap values less than 0.05.
